A team of researchers has launched the trial of a new needle-free COVID-19 vaccine that aims to protect against future variants of the infectious virus.
The participants, aged between 18 and 50 years, will take part in the trials at the NIHR Southampton Clinical Research Facility.
"As new variants emerge and immunity begins to wane, we need newer technologies," Jonathan Heeney of Cambridge University and Chief Executive of DIOSynVax, the maker of the vaccine, was quoted as saying.
While current COVID-19 vaccines use genes taken from the virus spike protein to encode antigens, which causes the immune system to produce antibodies, the new vaccine uses predictive methods to mimic the wider family of coronavirus antigens that researchers hope will give more protection.
The new vaccine is a spring-powered jet injection that delivers it into the skin, offering an alternative to those who have a fear of needle-based injections.
"This technology could give wide-ranging protection to huge number of people worldwide," Faust added.
(This story was published from a syndicated feed. Only the headline and picture has been edited by FIT)
(At The Quint, we question everything. Play an active role in shaping our journalism by becoming a member today.)
Published: undefined